Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Friday, 11th September at 12pm (AEST)
Please join Pitt Street Research co-founder and senior analyst, Stuart Roberts, for a briefing on Prescient Therapeutics.
In this session, Stuart will discuss:
- Insights on why biotech M&A activity is heating up and why big pharma and other groups might be interested in PTX.
- What he thinks about the potential value of PTX.
- How the technology works, why they are getting the results they are and the potential application to other forms of cancer.
This should be a fascinating session for anyone interested in biotech and an opportunity to ask questions with an experienced biotech analyst.
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
Can’t make this time, register to receive the replay.
Attend The Session
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services. Reach Investment Group Nominees Pty Ltd, a related entity of Reach Markets, holds options in Prescient Therapeutics Limited. Pitt Street Research Pty Ltd has been engaged and paid by the Prescient Therapeutics Limited for ongoing research coverage.
FEATURED SPEAKER
Stuart Roberts
Co-Founder and Senior Analyst
Stuart covered healthcare and biotechnology for the stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015 where he developed a reputation for detailed analysis on previously uncovered Life Science companies. After 15 months working for two ASX-listed drug development companies in 2015 and early 2016 he returned to equities research, co-founding Pitt Street Research.
Reach Markets provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
Reach Investment Group Nominees Pty Ltd, a related entity of Reach Markets, holds options in Prescient Therapeutics Limited. Pitt Street Research Pty Ltd has been engaged and paid by the Prescient Therapeutics Limited for ongoing research coverage.
This update is being hosted by Reach Markets Pty Ltd (CAR of AFSL 333297) and Reach does not assume responsibility for the accuracy or completeness of any information provided, and any communication from Reach has been prepared with all reasonable care and may be based on unverified information obtained from sources believed to be reliable. However, except to the extent required by law, Reach including its representatives, employees, agents or contractors are not liable to you for any loss or damage resulting directly or indirectly from access to information and do not accept any responsibility for errors and omissions, nor make any warranty or representation as to the reliability, suitability, confidentiality, accuracy, completeness or timeliness of information as it may change without notice and so Reach has no obligation to keep the information current.
Forward Looking Statements relate to intentions, future acts and events that are only predictions and are subject to risks, uncertainties and assumptions, which are outside the control of Reach. These may include commodity prices, currency fluctuations, economic and financial market conditions in various countries and regions, environmental risks and legislative, fiscal or regulatory developments, political risks, project delay or advancement, approvals and cost estimates. Actual values, results or events may be materially different to those expressed or implied and given these uncertainties, readers are cautioned not to place reliance on Forward Looking Statements. Information and views from third parties may be produced solely for convenience and are not endorsed nor reflective of Reach’s position.